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Abstract
Background
Motor neurone disease (MND) is a rare neurodegenerative condition, with poorly under-
stood aetiology. Large, population-based, prospective cohorts will enable powerful studies
of the determinants of MND, provided identification of disease cases is sufficiently accurate.
Follow-up in many such studies relies on linkage to routinely-collected health datasets. We
systematically evaluated the accuracy of such datasets in identifying MND cases.
Methods
We performed an electronic search of MEDLINE, EMBASE, Cochrane Library and Web of
Science for studies published between 01/01/1990-16/11/2015 that compared MND cases
identified in routinely-collected, coded datasets to a reference standard. We recorded study
characteristics and two key measures of diagnostic accuracy—positive predictive value
(PPV) and sensitivity. We conducted descriptive analyses and quality assessments of
included studies.
Results
Thirteen eligible studies provided 13 estimates of PPV and five estimates of sensitivity.
Twelve studies assessed hospital and/or death certificate-derived datasets; one evaluated
a primary care dataset. All studies were from high income countries (UK, Europe, USA,
Hong Kong). Study methods varied widely, but quality was generally good. PPV estimates
ranged from 55–92% and sensitivities from 75–93%. The single (UK-based) study of pri-
mary care data reported a PPV of 85%.
Conclusions
Diagnostic accuracy of routinely-collected health datasets is likely to be sufficient for identify-
ing cases of MND in large-scale prospective epidemiological studies in high income country
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settings. Primary care datasets, particularly from countries with a widely-accessible national
healthcare system, are potentially valuable data sources warranting further investigation.
Introduction
Motor neurone disease (MND) is a rare, rapidly progressive, neurodegenerative disease, which
leads to muscle wasting, weakness and usually death within a few years of onset[1]. The aetiol-
ogy is unclear and at present no cure is available. Further research that extends our current
understanding of the aetiology and pathophysiology of the disease is urgently needed to bring
us closer to developing effective treatment strategies.
Very large, population-based, prospective studies involving bio-sampling, detailed pheno-
typing and genotyping are ideal for investigating the determinants of diseases of complex aeti-
ology, including neurodegenerative diseases such as MND. Through identifying sufficiently
large numbers of incident cases of disease, such studies can provide adequate statistical power
to detect associations of environmental, lifestyle, biological and genetic exposures with disease
outcomes. They can also overcome the inherent limitations of retrospective case-control stud-
ies, including recall and reverse causation biases. A prominent example of such a study is UK
Biobank, which recruited 500,000 participants aged 40–69 years old between 2006 and 2010,
and has obtained a wealth of baseline information, stored bio-samples for current and future
assays, additional post-recruitment phenotyping, genome-wide genotyping and consent for
long term follow-up. Follow up of the participants’ health is chiefly via linkage to routinely-col-
lected national health datasets such as hospital admissions, death registrations and primary
care data. Data from UK Biobank are of substantial relevance to the international research
community, since they are available to any bona fide researcher worldwide who wishes to con-
duct health-related research for the benefit of the public’s health[2].
Cohort-wide linkage to routinely-collected health datasets, especially within the context of
a universally-available healthcare system such as the UK’s National Health Service (NHS), is a
comprehensive and cost-efficient method of case identification for large prospective studies
such as UKB. For aetiological research, the identification of disease cases within these cohorts
must be of sufficient accuracy, with a high positive predictive value (PPV) and reasonable sen-
sitivity. The accuracy of MND coding in these routinely-collected datasets therefore needs to
be understood.
PPV refers to the proportion of cases identified by codes in routinely-collected health data-
sets that are true cases. Sensitivity refers to the proportion of true cases in a population that
are identified by using codes in these health datasets. Specificity and negative predictive value
(NPV) are less important accuracy measures for case-control comparisons nested within pro-
spective studies as they tend to be high in these situations. In particular, NPV will be high
when most individuals in the population do not have the disease in question.
In this study we aimed to systematically review all studies that investigated the accuracy of
routinely-collected health datasets in identifying MND cases by comparing coded information
to a reference standard.
In this paper we use the term ‘motor neurone disease’ as an umbrella term for the group of
diseases of which amyotrophic lateral sclerosis (ALS) is one subtype, along with others such as
progressive bulbar palsy and progressive muscular atrophy. Elsewhere, particularly in North
America, the term ALS is used as the overarching term for this set of disorders. This difference
in the use of the term ALS should be borne in mind when interpreting the results of studies in
this review.
Routinely-collected health data in motor neurone disease
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Methods
Study protocol
The protocol for this systematic review was published prospectively on PROSPERO (www.crd.
york.ac.uk/PROSPERO, registration number 2015:CRD42015027985)[3].
Search strategy
We searched MEDLINE (Ovid), EMBASE (Ovid), CENTRAL (Cochrane Library) and Web of
Science (Thompson Reuters) for studies published between 1/1/1990-16/11/2015 that compared
MND coding in routinely-collected datasets to a reference standard (see S1 Table for search cri-
teria). We identified additional studies by searching the bibliographies of included studies and
from personal communication. Two authors (SH and TW) independently screened all titles,
abstracts and potentially relevant full text articles, resolving selection discrepancies through dis-
cussion and mutual consensus, and remaining areas of uncertainty through discussion with a
third, senior author (CLMS).
Eligibility criteria
Studies had to have been published in a peer-reviewed journal; to have compared routinely-
collected, coded datasets using internationally recognised coding systems (e.g. International of
Classification of Diseases, Read) to a reference standard for MND, based on medical diagnostic
review; to have reported PPV, sensitivity or both (or provided data from which these could be
calculated); and to have a sample size of10 MND cases (since smaller studies would have
limited precision). Studies estimating sensitivity had to have used a population-based reference
standard, with comprehensive MND case ascertainment (e.g. a population-based MND regis-
ter or similar). We did not impose any limitations based on published language or the country
in which the study was conducted.
Data extraction & analysis
Using pre-tested data extraction forms, two authors (SH and TW) independently extracted the
following information: first author, publication year, country from which the relevant coded
data were obtained, enrolment period, study population characteristics, study size, routine
dataset(s) assessed (hospital, deaths, primary care), coding system, codes and coding positions
(primary, secondary or any position) used to identify cases, reference standard used, PPV and/
or sensitivity with their 95% confidence intervals (or data to calculate these). Any discrepancies
were discussed and resolved with a third, senior author (CLMS). If data required to extract a
PPV or sensitivity estimate were unclear or omitted from the published manuscripts, we con-
tacted the original study authors for clarification.
Where appropriate, our approach used features of the methodology developed for system-
atic reviews of diagnostic test accuracy studies. However, there were key differences. In partic-
ular, for many studies that investigated PPV, it was not possible to also calculate sensitivity
because the total number of MND cases (true positives and false negatives) in the relevant pop-
ulation was not known. We adapted the Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS-2) tool to evaluate study quality (S1 File)[4]. Two authors (SH & TW) completed
the assessments of risk of bias and applicability (relevance to the study question) for the follow-
ing QUADAS-2 categories: patient selection, source of coded data (including the codes used to
identify cases), reference standard and study flow (e.g. whether all cases were accounted for).
We assessed the risk of bias and the applicability of studies with respect to our review purpose,
not on the quality of the paper in general. We did not exclude studies on the basis of quality.
Routinely-collected health data in motor neurone disease
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Where data were available, we calculated 95% confidence intervals for PPV and sensitivity
directly. We generated statistical measures of heterogeneity using I2 and chi-squared methods,
but we focussed on descriptive assessments of heterogeneity based on evaluating study meth-
odologies. We did not perform a formal meta-analysis as the substantial heterogeneity in
methodologies between studies would make any summary measure of PPV or sensitivity
potentially misleading. Instead, we performed a descriptive analysis, and considered factors
that might influence PPV and sensitivity through visual inspection of the range of values in a
forest plot. We also investigated within-study comparisons of PPV values with respect to char-
acteristics reported by at least two studies (age, sex and coding position). We performed statis-
tical analyses with StatsDirect3 software.
Results
Study selection
Thirteen studies fulfilled the eligibility criteria and were included in the review[5–17]. A flow
diagram of the study selection process detailing reasons for exclusion is displayed in Fig 1.
Study characteristics
Across the 13 studies there were 13 estimates of PPV[5–16] and five of sensitivity[7,8,16,17],
with one study contributing separate PPV and sensitivity estimates for hospital and death data
[7]. Characteristics of studies reporting PPV and sensitivity of a coded MND diagnosis are
summarised in Tables 1 and 2 respectively. Comparison of the key study characteristics
detailed in these tables reveals the heterogeneity of methodological approaches.
All studies were based in high income countries. Three were from the UK[5,7,9], seven
from other European countries[6,8,10,12,13,16,17], two from the USA[14,15] and one from
Hong Kong [11]. For studies reporting PPV, sample size (number of participants with an
MND code) ranged from 48–433; for those reporting sensitivity, sample size (number of par-
ticipants known to have MND in the population-based reference standard) ranged from 95–
488. The studies were conducted over a range of different time periods. Eight began before
2000, and three of these began prior to 1990. The vast majority of studies included assessment
of hospital and/or death certificate-derived datasets, with only one study assessing primary
care data[5].
Hospital and death data were coded using various different versions of the World Health
Organisation International Classification of Diseases (ICD) system[18] (see Table 3). Based on
the codes chosen, studies variably investigated all-cause MND, amyotrophic lateral sclerosis
(ALS) or other MND subtypes. The single study that used primary care data did not report
which coding system it used[5], but, since the study was UK-based, this is likely to have been
the Read coding system, used since 1985 in UK primary care[19].
The broad categories of diagnostic reference standard used were medical record review,
presence in an MND patient register and direct patient assessment, although methodological
details and diagnostic criteria for case confirmation varied. Four studies[6,11–13] used either
the original or revised El Escorial criteria[20,21] to confirm a diagnosis of MND. These criteria
require evidence of upper and lower motor neurone involvement, with a progressive spread of
the regions affected. Depending on the clinical evidence obtained, the original El Escorial crite-
ria identify five levels of diagnostic certainty: suspected, possible, laboratory-supported proba-
ble, probable and definite[20], while the revised El Escorial criteria identify three levels:
possible, probable and definite[21]. Studies differed in the diagnostic certainty threshold
required (Table 1).
Routinely-collected health data in motor neurone disease
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Quality assessment
Studies generally performed well in the subjective quality assessment (S2 Table). We did not
consider any to be of high risk of bias or to have substantial applicability concerns. However,
we rated 12 of the 13 studies as ‘unclear’ for at least one category, either because there was
insufficient information to assess the category, or because we could not be sure what effect the
reported methodology for that category would have on bias or applicability.
Fig 1. Selection of studies. *Correspondence: Short letters to journal editors and similar forms of communication
doi:10.1371/journal.pone.0172639.g001
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PPV of routinely-collected datasets in MND case identification
There were thirteen estimates of PPV, eight based on hospital admissions data[6–10,12–14],
one on hospital admissions and outpatient data combined[11], three on death data[7,15,16]
and one on primary care data[5]. PPV results stratified by data source are summarised in Fig
2. Reported PPVs ranged from 55%-92%; more than half of these (including over half of the
total number of patients studied) were80%. One included study that assessed hospital
Table 2. Studies reporting the sensitivity of an MND code in routinely collected datasets, separated by dataset evaluated.
First
author
Country Study
period
Study population
used to generate
reference
standard
Study
size
(n)
Routine
dataset
Coding
system
Code(s)
assessed
Coding
position
assessed
Disease
investigated
Sensitivity
summary
Notable study
characteristics
Chancellor
19937
UK 1989–
1990
MND cases as
listed on the
Scottish Motor
Neurone Disease
Register
(SMNDR)
317 H ICD-9 335 Any MND Proportion
of MND
cases with
ICD-9
discharge
code 335.2
Chio´ 20028 Italy 1995–
1996
ALS cases as
listed on The
Piemonte and
Valle d’Aosta
Register for ALS
(PARALS))
213 H ICD-9 335.2 Any ALS Proportion
of ALS
cases with
ICD-9
discharge
code 335.2
Analysis limited
to incident
cases
Chancellor
19937
UK 1989–
1990
Deceased
Scottish Motor
Neurone Disease
Register
(SMNDR) cases.
95 D ICD-9 335 Any MND Proportion
of death
certificates
of known
MND cases
that report
MND
Chio´
199217
Italy 1970–
1985
Deceased ALS
cases
ascertained from
multiple
overlapping
sources (hospital
archives,
neurophysiology
laboratories,
social security
records and files
of neurologists)
488 D Unclear Unclear Primary ALS Proportion
of death
certificates
of known
ALS cases
that report
ALS
Yeo
201016
Republic
of Ireland
2002–
2006
Deceased cases
registered with
the Irish Register
for ALS/MND
398 D ICD-9 Unclear Any ALS/MND Proportion
of death
certificates
of known
ALS/MND
cases that
report ALS/
MND
Study population: Source of cases including method of case ascertainment. Study size: Number of known MND cases for which a code was sought. Routine
dataset: The routinely collected source of coded datasets; H: hospital admissions data, D: death certification. MND codes: ICD-9 & ICD-9-CM:
335.2 = MND, 335.20 = amyotrophic lateral sclerosis, 335.21 = progressive muscular atrophy, 335.22 = progressive bulbar palsy, 335.23 = pseudobulbar
palsy, 335.24 = primary lateral sclerosis, 335.29 = other motor neurone disease. ICD-10: G12.2 = MND, G12.20 = unspecified, G12.21 = amyotrophic
lateral sclerosis, G12.22 = progressive bulbar palsy, G12.29 = other motor neurone disease. Coding position: Position at which a code for MND was
assessed in the major analysis in the study.
doi:10.1371/journal.pone.0172639.t002
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admissions data was of lower overall quality[12], but its PPV was not an outlier. PPVs for
MND codes recorded in three studies of death certificate data ranged from 64–90%[7,15,16];
two of these (including around two thirds of the patients in the relevant studies) were80%
[7,16]. In the nine studies of hospital data, PPVs ranged from 55–92%[6–14]. Four of these
nine studies reported PPVs >80%[9,10,13,14]. Based on the results of a single UK-based study,
primary care data appeared to have a good PPV (85%)[5].
Sensitivity of routinely-collected datasets in MND case identification
There were five estimates of sensitivity, two from hospital discharge data[7,8] and three from
mortality data[7,16,17] (Fig 3). No studies assessed the sensitivity of primary care data. All of
the sensitivities reported were75% and the values were less variable (range: 75–93%) than
the PPVs. All studies reporting sensitivity were of high quality in the QUADAS-2 assessment.
There was no observable difference between the sensitivity measures arising from death or
hospital data. The studies assessing death data reported sensitivities of 75–93%[7,16,17] and
those evaluating hospital data reported sensitivities of 79–84%[7,8].
UK-based routinely-collected datasets
The UK NHS provides an ideal substrate for data linkage studies as there is a single provider of
healthcare services. Of particular relevance for researchers worldwide using UK Biobank (and
other large population-based UK cohorts that have linkage to routinely-collected healthcare data-
sets), the three UK-based studies reported some of the best performing results with respect to PPV
and sensitivity[5,7,9] (Figs 2 and 3) and also scored well on the QUADAS-2 quality assessments.
Within-study comparisons
Four studies conducted within-study analyses of the effects of age, gender or coding posi-
tion on PPV estimates. However, sufficient data were not available to permit a consistent
Table 3. International Classification of Diseases (ICD) codes for motor neurone disease and its
subtypes.
ICD system Code Diagnosis
ICD-8 348 Motor neurone disease
348.0 Amyotrophic lateral sclerosis
348.1 Progressive bulbar palsy
348.2 Other progressive muscular atrophy
348.9 Other and unspecified manifestations
ICD-9 335.2 Motor neurone disease
335.20 Amyotrophic lateral sclerosis
335.21 Progressive muscular atrophy
335.22 Progressive bulbar palsy
335.23 Pseudobulbar palsy
335.24 Primary lateral sclerosis
335.29 Other motor neurone disease
ICD-10 G12.2 Motor neurone disease
G12.20 Unspecified
G12.21 Amyotrophic lateral sclerosis
G12.22 Progressive bulbar palsy
G12.29 Other motor neurone disease
doi:10.1371/journal.pone.0172639.t003
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assessment of the statistical significance of the differences reported. Results are displayed in
Table 4.
Two studies of hospital data and one of primary care data assessed the effect of age [5,8,12].
While the small primary care study found no difference in PPV between participants aged
70 and >70 years [5], the two larger studies of hospital data each reported a decline in PPV
above the age of 70 to 75 years[8,12]. One of these reported that PPV increased with advancing
age until ultimately falling in the elderly[8].
Two studies of hospital data examined the effect of sex on PPV[8,12]. Both reported a
higher PPV in women. The difference was more substantial in one study (male PPV: 78%,
female PPV: 89%)[12], than the other (male PPV: 60%, female PPV: 62%)[8].
Two studies of hospital data investigated the effect of the coding position of the recorded
MND diagnosis [8,14]. Both found that codes in the primary position had a higher PPV than
Fig 2. PPV of an MND code, stratified by type of routinely-collected dataset. Boxes weighted by study size. PPV: Positive predictive value. Study size:
Number of cases with MND codes that were assessed. Routine dataset: The routinely collected source of coded datasets P: primary care data, H: hospital
data, D: death certificate data. Heterogeneity measures: I2 = 97%, Chi-squared = 321.6 (df = 12) p<0.0001.
doi:10.1371/journal.pone.0172639.g002
Fig 3. Sensitivity of an MND code, stratified by type of routinely-collected dataset. Boxes weighted by study size. Study size: Number of known MND
cases for which a code was sought. Routine dataset: The routinely collected source of coded datasets. P: primary care data, H: hospital data, D: death
certificate data. Heterogeneity measures: I2 = 83%, Chi-squared = 23.0 (df = 4) p = 0.0001.
doi:10.1371/journal.pone.0172639.g003
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those in any position, but relying on the primary position alone substantially reduced the num-
ber of cases identified.
Discussion
There is no widely-agreed level of the accuracy required for identifying disease cases for
research using routinely-collected health datasets, and acceptable PPV and sensitivity thresh-
olds will differ depending on the specific study purpose. In this systematic review we have
shown that although reported accuracy estimates for identifying MND cases from such data-
sets vary widely, individual datasets often achieve PPV or sensitivity values of80%, and can
reach>90%.
False positive cases identified from coded data can be due to diagnostic or administrative
errors. Given that–at least in many high income countries–the diagnosis of MND is usually
made or confirmed by a specialist[22] we would expect diagnostic error to be low. However,
clinical experience suggests that there are many patients in whom the diagnosis of MND is
highly likely despite not meeting formal diagnostic criteria. Considering such patients to be
Table 4. Within-study sub-group analyses.
The effect of age on PPV
First author Publication year Routine dataset Study size Age PPV
Alonso5 2009 P 65 70 85%
>70 85%
Chio´8 2002 H 433 20–29 50%
30–39 53%
40–49 52%
50–59 66%
60–69 70%
70–79 61%
80–89 26%
Kioumourtzoglou12 2015 H 173 <55 78%
55–74 82%
>75 68%
The effect of gender on PPV
First author Publication year Routine dataset Study size Gender PPV
Chio´8 2002 H 433 Male 60%
Female 62%
Kioumourtzoglou12 2015 H 173 Male 78%
Female 89%
The effect of coding position on PPV
First author Publication year Routine dataset Study size Coding position PPV
Chio´8 2002 H 433 Any 61%
309 Primary 74%
Stickler14 2011 H 336 Any 92%
101 Primary 97%
PPV: Positive predictive value. Routine dataset: The routinely collected source of coded datasets. P:
primary care data; H: hospital discharge data; D: death certification. Study size: Number of MND codes
assessed (sum of true positives and false positives). TP: True positive. Number of TP cases: Total number
of true positive cases, i.e. those for whom a diagnosis of MND was confirmed following application of
reference standard. Coding position: Position at which a code for MND was recorded.
doi:10.1371/journal.pone.0172639.t004
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‘false positives’ in validation studies of coded data may result in falsely-low PPV estimates. The
sensitivity of coded hospital admissions data for the identification of MND cases will depend
on how likely MND patients are to be admitted to hospital during the course of their illness.
This is likely to vary by geographic location, with differences in healthcare access and provi-
sion. Since MND usually leads to death within a few years of diagnosis, one would expect
coded death data to be a sensitive source of MND case identification, as we observed.
Primary care data appears to be a promising source of MND case ascertainment for prospec-
tive studies based in countries with universally-accessible primary health care. Primary care in
the UK is a free, comprehensive and lifelong service, in which general practitioners (GPs) act as
gatekeepers to more specialist services, meaning that most individuals with an active diagnosis
are likely to present to primary care at least once. Furthermore, GPs hold comprehensive medi-
cal notes for their patients, including correspondence from secondary care, resulting in diagno-
ses made in secondary care being coded in primary care datasets. Primary care data may
therefore prove to be a rich resource for the study of MND epidemiology, particularly in coun-
tries without a national MND register. However, since only one small study reported the PPV
of MND codes recorded in primary care data[5], and none reported the sensitivity, future inves-
tigation of the value of coded primary care data in MND case ascertainment is warranted.
Within-study analyses minimise confounding by variation in study methodology and set-
ting, and so should enable more reliable evaluation of factors affecting the accuracy of case
identification than between-study comparisons. However, such analyses were only available
for a small number of studies and factors potentially influencing accuracy. While they showed
that limiting case ascertainment to those recorded at the primary coding position may increase
PPV, this was at the expense of the number of cases identified. In population-based, prospec-
tive studies such as UKB, methods of identifying disease cases with a high PPV are generally
prioritised over those with a high sensitivity, as the effect of any false negatives (cases that are
misidentified as controls) in case-control and case-cohort studies is diluted amongst the very
large number of control subjects[23]. However, sensitivity needs to be sufficient to generate
large numbers of cases for adequate statistical power as well as to ensure that representative
cases are ascertained across the disease spectrum. It is important to strike a balance between
the comprehensiveness of case ascertainment (reflected by high sensitivity) and the proportion
of the pool of cases identified that are true positives (PPV).
Heterogeneity of accuracy estimates
The wide range of reported PPV and sensitivity measures likely reflects variation in study
methodologies as well as between the data sources.
The method of case confirmation (reference standard) could influence reported estimations
of accuracy. Studies differed in their application of the El Escorial criteria, while subjects that
could not be traced were counted as false positives in some studies but excluded from the anal-
ysis in others.
The system used to assign codes to diagnoses could also account for some variation. Most
included studies assessed data coded using ICD-9 or ICD-10, which differ with respect to cod-
ing of MND subtypes: ICD-10 lists only ALS and progressive bulbar palsy as specific subtypes
of MND, whereas ICD-9 permits sub-classification of five subtypes. However, variable study
methods and characteristics precluded a reliable assessment of the effect of coding system on
accuracy. A further issue relates to a problem with MND subgroup coding in an early version
of ICD-10[9], in which the condition progressive supranuclear palsy (PSP) was wrongly given
the code G12.2 for MND. This may affect the results of studies coded before this problem was
rectified, as patients with PSP would have been given an MND code and then counted as false
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positives (e.g., Doyle et al. [2012] discovered that 8% of cases with the ICD-10 code G12.2 were
miscoded due to this error[9]).
Variation may also arise from the specific codes chosen. Included studies variably investi-
gated MND, ALS, and/or other specific disease sub-types. Studies that used a broad code, such
as the ICD-9 335.2, would include rarer subtypes such as progressive muscular atrophy or pri-
mary lateral sclerosis (335.21 and 335.24 respectively) in addition to ALS, although the effect
of including these very rare subtypes is likely to be minimal, as they are much less common
than the ALS variant. More importantly, the choice of code to identify the relevant condition
was sometimes inaccurate, leading to misclassification. For example, the ICD-9 code 335.2
which represents a diagnosis of MND, was often used interchangeably with code 335.20 repre-
senting ALS. Such usage may have led to the inappropriate classification of some outcomes as
false positives within studies, but as clinical information for every possible case was not avail-
able, we were unable to determine the effect on results.
Although we cannot estimate their effects quantitatively, these methodological issues are
likely to have caused spuriously low as opposed to falsely elevated PPV estimates, suggesting
that the results generally represent minimum estimates of PPV.
Increasing the accuracy of case identification
Accurate case ascertainment may be optimised by an algorithm which draws upon multiple
sources, to improve both PPV and sensitivity. For example, one study that did not meet the eli-
gibility criteria for this review as it combined routine and non-routine data sources (insurance
data, death registrations, reports from local neurologists and records from the ALS Associa-
tion) achieved an improvement in PPV from 84% with single sources to 98% with combined
sources[24]. An additional method of improving PPV might be to only include cases that
appear more than once within a dataset or in more than one dataset. Where possible, linkage
to robust, comprehensive, national disease registers such as the population-based Scottish
MND Register[25] is likely to be a powerful way to increase both sensitivity and PPV.
Strengths and limitations
Our review benefits from rigorous methodology, including prospective protocol publication,
comprehensive search criteria, and involvement of two independent authors in study screening,
quality assessments and data extraction. While some relevant studies may have been missed,
our extensive search criteria should minimise this possibility. We included all identified, eligible
studies to retain a comprehensive, systematic approach and avoid study selection bias. While
including studies of lower quality could theoretically affect our results, such studies did not have
extreme PPV or sensitivity values. Publication or selective reporting biases could have influ-
enced our results, since studies showing high accuracy might be published or reported more
often than those with lower accuracy. However, such effects are difficult to assess meaningfully
in this type of review, and so we did not attempt formally to estimate these potential biases.
Lastly, PPV increases with the prevalence of the condition of interest in the study population,
meaning that PPVs will tend to be higher for common conditions. We were unable to assess the
underlying prevalence of MND across the study populations, but given that MND is generally
rare, we believe this is unlikely to have substantially affected variability of our PPV estimates.
Conclusions
In general, PPV and sensitivity of routinely-collected health data in identifying MND cases are
likely to be sufficient for many epidemiological studies investigating the determinants of MND.
However, in view of the range of reported results, prospective studies may wish to perform their
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own validation studies to evaluate the PPV and/or sensitivity for their particular study setting
and population. For UK Biobank, which has obtained primary care data for many participants,
further studies that assess the improvements in accuracy achieved by identifying MND cases
through primary care data in addition to hospital and death data, will be helpful. In the mean-
time, scientists interested in using UK Biobank or other UK-based prospective studies with data
linkage for MND-related research can be reassured that PPV and sensitivity in UK studies of
hospital admissions and death registration data are among the highest reported for MND, while
the one UK-based primary care study showed promising results. In view of the different advan-
tages associated with each type of dataset and the additional factors that influence the accuracy
of a coded diagnosis of MND, the development of a case identification algorithm based on mul-
tiple overlapping sources may be particularly valuable and merits further investigation.
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